Urologix (ULGX) Shares Rally as Dougherty Starts at Buy, $2 Price Target
Tweet
Share
E-mailGet Alerts ULGX Hot Sheet
Price: $0.00 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Dougherty & Co initiated coverage on Urologix (NASDAQ: ULGX) with a Buy rating and a $2 price target in a mid-day research note Tuesday.
The firm's Deepak Chaulagai called Urologix the "leader in in-office BPH treatment." The analyst said following the 2011 acquisition of a license for the Prostiva RF therapy system, "the company now has a dominant market share (~60%), a larger sales force, and has expanded its customer base by 70% with only a small overlap between the CTT and Prostiva customer base." Chaulagai believes BPH represents an "undeserved market."
With shares of Urologix now up about 12.5 percent to $0.90, the analyst's new price target implies potential upside of about 122 percent.
For an analyst ratings summary and ratings history on Urologix click here. For more ratings news on Urologix click here.
The firm's Deepak Chaulagai called Urologix the "leader in in-office BPH treatment." The analyst said following the 2011 acquisition of a license for the Prostiva RF therapy system, "the company now has a dominant market share (~60%), a larger sales force, and has expanded its customer base by 70% with only a small overlap between the CTT and Prostiva customer base." Chaulagai believes BPH represents an "undeserved market."
With shares of Urologix now up about 12.5 percent to $0.90, the analyst's new price target implies potential upside of about 122 percent.
For an analyst ratings summary and ratings history on Urologix click here. For more ratings news on Urologix click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Canaccord Starts Galiano Gold (GAU:CN) at Buy
- UBS Starts Schrodinger (SDGR) at Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
